Table 1 Patient characteristics
Characteristic (n = 43 patients) | Value* |
|---|---|
Median age, range | 65 (47–79) years |
Median weight, range | 87 (63–120) kg |
Median PSA level, range at imaging | 10.3 (2.62–110) ng/mL |
Risk group classification based on D’Amico’s classification system [13] | |
Number of patients at intermediate risk | 14 (32.5%) |
Number of patients at high risk | 29 (67.5%) |
Number of patients with > 5% risk of lymph node involvement according to Briganti et al. [14] | 37 (86%) |
Gleason score** | |
6 | 2 (4.6%) |
7–8 | 33 (76.8%) |
9–10 | 8 (18.6%) |
ISUP grade (2014 ISUP grading system) | |
1 | 2 (4.6%) |
2 | 14 (32.6%) |
3 | 8 (18.6%) |
4 | 5 (11.6 %) |
5 | 14 (32.6 %) |
Clinical T stage | |
cT1-2a | 27 (62.8%) |
cT2b | 7 (16.3%) |
cT2c | 4 (9.3%) |
cT3-4 | 5 (11.6%) |